Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Gynecologic 1Breast 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Sexual Dysfunction, Physiological 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Depression 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1Anxiety Disorders 1

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 456Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Has results × Dehydroepiandrosterone × Clear all
NCT01376349 2019-02-07

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

Alliance for Clinical Trials in Oncology

Phase 3 Completed
464 enrolled 8 charts
BreastGynecologicOther

Carcinoma, Ovarian Epithelial, Anxiety Disorders, Breast Neoplasms, Uterine Cervical Neoplasms, Depression, Fallopian Tube Neoplasms, Sexual Dysfunction, Physiological, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡